A Study of MIRCERA for the Intrapetient Variability of Hemoglobin Levels in Patients With Chronic Renal Anemia (RIVAL)

Retrospective Study on Intrapatient VAriabiLity of the Hemoglobin Levels in Anemic CKD Patients in Predialysis (Stage 3-4) and Dialysis (Stage 5) Treated With MIRCERA® (RIVAL Study)

This retrospective observational study will assess the incidence of hemoglobin cycling in chronic kidney disease (stage 3, 4, and 5) patients with renal anemia treated with Mircera (methoxy polyethylene glycol-epoetin beta). Data will be collected from each patient from a 9-month treatment period.

Inclusion Criteria:

• Adult patients, >/= 18 years of age
• Chronic kidney disease in predialysis (stage 3 and 4) and dialysis
• Renal anemia treated with Mircera according to label for at least 9 months before date of signed informed consent

Exclusion Criteria:

• Participation in an interventional clinical trial within the retrospective observation period
• Contraindications to Mircera administration as per label or judged by the investigator